Seres Therapeutics, Inc. (NASDAQ:MCRB) - Cantor Fitzgerald increased their FY2017 EPS estimates for shares of Seres Therapeutics in a report released on Tuesday. Cantor Fitzgerald analyst W. Tanner now anticipates that the biotechnology company will post earnings per share of ($2.45) for the year, up from their previous forecast of ($2.62). Cantor Fitzgerald has a “Buy” rating and a $16.00 price target on the stock. Cantor Fitzgerald also issued estimates for Seres Therapeutics’ FY2018 earnings at ($2.92) EPS.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company had revenue of $3 million for the quarter, compared to analysts’ expectations of $3 million. During the same period in the prior year, the business earned ($0.70) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Forecast for Seres Therapeutics, Inc. (NASDAQ:MCRB) Issued By Cantor Fitzgerald” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/08/12/fy2017-earnings-forecast-for-seres-therapeutics-inc-nasdaqmcrb-issued-by-cantor-fitzgerald.html.
Several other research analysts have also recently commented on MCRB. Canaccord Genuity set a $20.00 target price on shares of Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BidaskClub cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Zacks Investment Research cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $19.00 target price (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. Finally, ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Seres Therapeutics has an average rating of “Buy” and a consensus price target of $17.00.
Seres Therapeutics (MCRB) opened at 13.77 on Thursday. The stock’s market cap is $557.85 million. The company’s 50 day moving average price is $12.55 and its 200-day moving average price is $10.69. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $15.09.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its position in Seres Therapeutics by 45.7% in the second quarter. Dimensional Fund Advisors LP now owns 36,600 shares of the biotechnology company’s stock valued at $414,000 after buying an additional 11,488 shares during the period. Citadel Advisors LLC boosted its position in Seres Therapeutics by 94.6% in the second quarter. Citadel Advisors LLC now owns 40,212 shares of the biotechnology company’s stock valued at $455,000 after buying an additional 19,550 shares during the period. Parametric Portfolio Associates LLC boosted its position in Seres Therapeutics by 2.7% in the second quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 580 shares during the period. Advisor Group Inc. boosted its position in Seres Therapeutics by 100.7% in the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 7,050 shares during the period. Finally, ARK Investment Management LLC boosted its position in Seres Therapeutics by 21.5% in the second quarter. ARK Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after buying an additional 135,276 shares during the period. Institutional investors and hedge funds own 75.31% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
